Clinical Trial Update: Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating selecting the appropriate population for adding a CDK4/6 inhibitor to neoadjuvant endocrine therapy in locally advanced HR-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor Positive Breast Cancer

Snippet

Sponsor: Yongsheng Wang | Conditions: Locally Advanced Breast Cancer, Hormone Receptor Positive，HER2-negative Breast Cancer | Phase 4 | Status: UNKNOWN